Until then, drug prices will probably outstrip inflation, and pharmaceutical companies such as AbbVie, Amgen, Teva, AstraZeneca will likely continue to make money -- even recommended Tva Pharmaceutical Industries, whose chairman is a former "Bad Boy of Pharma" -- who tried last year to raise the price of an acquired therapeutic known as Daraprim by more than 5,500% without altering the formulation or manufacturing process one pixel.